02 March 2019 | Bern, Switzerland

Update in Genitourinary Cancers

ASCO_Montage_IC_cropped

Many thanks to everyone, who attended the ASCO Direct™ GU Highlights Meeting in Bern, Switzerland on Saturday, 02 March 2019.

The ASCO Direct GU Highlights Meeting was a full-day educational program containing selected original sessions from the 2019 Genitourinary Cancers Symposium on urothelial carcinoma, prostate, bladder, renal, penile, urethral, and testicular cancers. Attendees had the opportunity to view the original sessions with most actual clinical data in uro-oncology and discuss the clinical relevance and implications for Swiss treatment landscape of the presented evidence with their colleagues.
Here are the program and details of the ASCO Direct™ GU Highlights Meeting 2019. We are looking forward to organize the Highlights meeting 2020, the related information will be available later this year. If you would like any further information, please feel free to contact us at asco@springer.com

Independent scientific committee

The program is supervised by an independent scientific committee:

  • Joerg Beyer, Inselspital Bern
  • Martin Spahn, Hirslanden
  • Aurelius Omlin, Kantonsspital St. Gallen
  • Dominik Berthold, Centre Hospitalier Universitaire Vaudois

Program

Saturday, March 2nd 2019

09:00-09:10 Welcome & Start of the programJörg Beyer
09:10-10:10 Prostate CancerChair: Aurelius Omlin
Martin Spahn Diagnostic procedures in prostate cancer diagnosis: State-of-the-art
Andrew Vickers PSA screening – towards a harm reduction approach
Samir Taneja The role of MRI in target biopsy
Scott Williams A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer
10:10-10:30 Break
10:30-12:30 Prostate CancerChair: Martin Spahn
Aurelius Omlin Controversies in PCa
Nicolas J. Van As PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
Andrew J. Amstrong Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
Karim Fizazi ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
Evan Yu Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
12:30-13:30 Lunch
13:30-16:00 Urothelial Bladder CancerChair: Dominik Berthold
Jörg Beyer What are the issues in localized urothelial bladder cancer
Michael Cookson Radical Cystectomy Is the Best Option for Muscle-Invasive Bladder Cancer
Jason A. Efstathiou Trimodality Therapy Is the Best Option for Muscle-Invasive Bladder Cancer
Andrea Necchi Perioperative Immunotherapy in Urothelial Carcinoma: State of Existing Evidence
James L. Gulley Key Note Lecture: Immunotherapy Across Genitourinary Malignancies
16:00-16:30 Break
16:30-18:00 Renal CancerChair: Jörg Beyer
Dominik Berthold New standard in RCC: TKI, Immunotherapy or both
Brian M. Shuch When to Obtain Genetic Testing for Syndromic Renal Cell Cancer
Paul Russo Lessons learned from Carmena: Surgeon’s Perspective
Lauren C. Harshman Lessons learned from Carmena: Medical Oncologist’s Perspective
Thomas Powles Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study
Daniel Y. C. Heng Beyond First-Line Systemic Therapy for Metastatic Renal Cell Cancer
18:00-18:20 Important trials and activities in Switzerland in urogenital cancer in 2018
Aurelius Omlin Prostate Cancer
Martin Spahn Urothelial bladder Cancer
Jörg Beyer Testicular Cancer
Dominik Berthold Renal Cell Cancer
18:20-18:30 Closing Remarks

Program may be subject to change

Registration

The registration fee is 115 CHF and will be donated to the Movember Foundation.

Benefits of this meeting

  • No jet lag
  • No extended absence from your clinic
  • Access to all videos and slides from ASCO GU 2019 via the ASCO® Meeting Library
  • Reduced travel time to stay informed about the latest news and developments presented at the ASCO GU symposium
  • Discussion with Swiss experts and colleagues

Contact

Please feel free to contact us at asco@springer.com if you have any questions.

Location

Kongress + Kursaal Bern AG
Kornhausstrasse 3
3000 Bern 22
www.kursaal-bern.ch

Sponsored by:

logo
logo
logo

ASCO Direct™ Highlights is an officially licensed program of the American Society of Clinical Oncology®. ASCO® is a registered trademark of the American Society of Clinical Oncology. All rights reserved. ASCO does not endorse any health care product, therapy, diagnostic test or device.